Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Botanix Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2019 Planned initiation date changed from 26 Jan 2016 to 13 Feb 2019.
    • 30 Jan 2019 Status changed from planning to not yet recruiting.
    • 23 Jul 2018 According to a Botanix Pharmaceuticals media release, preparation is underway for this Phase II trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top